Mabwell (Shanghai) Bioscience Co., Ltd.
邁威(上海)生物科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2493)

(1) POLL RESULTS OF THE 2026 FOURTH EXTRAORDINARY GENERAL MEETING; AND (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Reference is made to the circular of Mabwell (Shanghai) Bioscience Co., Ltd. (the "**Company**") dated August 30, 2026 (the "**Circular**") in relation to the 2026 fourth extraordinary general meeting (the "**EGM**"). Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

CONVENING AND ATTENDANCE OF THE EGM

The EGM was held at Conference Room 103, Building 3, Chuangxiang Park, No. 576, Libing Road, Pudong New Area, Shanghai, China, on Thursday, September 17, 2026. The EGM was convened by the Board and presided over by Dr. Liu Datao, Chairman and the Executive Director. All Directors attended the EGM either in person or by electronic means.

The EGM was legally and validly convened in compliance with the requirements of the relevant laws and regulations of the PRC and the Articles of Association of the Company.

As at the date of the EGM, (i) the total number of the issued Shares of the Company was 446,730,200 Shares, comprising 399,600,000 A Shares and 47,130,200 H Shares; (ii) the total number of treasury shares held by the Company was 1,192,369 A Shares and no voting right of treasury shares has been exercised at the EGM; (iii) there was no repurchased share which was pending cancellation and should therefore be excluded from the total number of issued shares entitling holders to attend and vote on all the resolutions at the EGM. The total number of Shares entitling the Shareholders to attend and vote on the resolution was 445,537,831 Shares. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the proposed resolution at the EGM as set out in Rule 13.40 of the Hong Kong Listing Rules and no Shareholder that was required under the Hong Kong Listing Rules to abstain from voting at the EGM. None of the Shareholders has stated their intention in the Circular to vote against or to abstain from voting on the resolution proposed at the EGM.

Voting for the resolution proposed to the Shareholders at the EGM was conducted by poll, which included both onsite voting by poll and, for A Shareholders only, online voting by poll. Tricor Investor Services Limited, the Company's H Share registrar, served as the scrutineers in respect of the vote-taking of H Shares at the EGM.

POLL RESULTS OF THE EGM

The poll results are set out below.

<table>
<tr><th colspan="2" rowspan="2">Ordinary Resolutions[(1)]</th><th colspan="3">Number of Votes
&
Percentage of Voting Shares</th><th rowspan="2">Passed by Shareholders</th></tr>
<tr><th>For</th><th>Against</th><th>Abstain</th></tr>
<tr><td>1.</td><td>Proposal on Entering into the License Agreement and Related-party Transaction with SynuSight.</td><td>201,182,513
(99.9099%)</td><td>172,603
(0.0857%)</td><td>8,775
(0.0044%)</td><td>Yes</td></tr>
<tr><td>2.</td><td>Proposal on the Joint Application for a Science and Technology Project with SynuSight and Related-party Transaction.</td><td>201,182,513
(99.9099%)</td><td>172,603
(0.0857%)</td><td>8,775
(0.0044%)</td><td>Yes</td></tr>
<tr><td colspan="2">Special Resolution[(1)]</td><td colspan="4"></td></tr>
<tr><td>3.</td><td>Proposal on the Change in the Scope of Business of the Company, Amendments to the Articles of Association and the Registration of Industrial and Commercial Changes.</td><td>201,172,813
(99.9051%)</td><td>162,603
(0.0808%)</td><td>28,475
(0.0141%)</td><td>Yes</td></tr>
</table>

Notes:

(1) For details of the resolutions, please refer to the Circular.

(2) An ordinary resolution is passed by more than half of the votes cast in favor of it, and a special resolution is passed by more than two-thirds of the votes cast in favor of it.

WITNESS BY PRC LEGAL ADVISERS

The EGM was witnessed by Merits & Tree Law Offices, the PRC legal advisers of the Company, who issued a legal opinion, pursuant to which they are of the view that the convening of and the procedures for holding the EGM, the eligibility of the convener, and attendees and the voting procedures were in compliance with the requirements of the relevant laws and regulations and the provisions of the Articles of Association of the Company and that the poll results were valid.

THE PROPOSED CHANGE IN THE SCOPE OF BUSINESS AND THE PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The change in the scope of business is intended to cater for the business development of the Group and to optimise the governance of the Company. The additional business scope items support the continued development of the Group's pharmaceutical research and development capabilities and related operational and commercialisation activities. The development of human genetic diagnosis and treatment technologies and R&D and application of cell-based technologies accommodate continued technological exploration and the evaluation of emerging technologies relevant to pharmaceutical research and development, drawing on the Group's existing research capabilities and experience. Agricultural scientific research and experimental development includes preliminary exploration of broader potential applications, such as adapting the Group's existing research capabilities and drug-development technologies for companion animals. Corporate management consulting and information consulting services (excluding information consulting services subject to licensing) accommodate incidental sharing of management experience and scientific, technical and industry information in connection with the Group's existing operations, business relationships, research and development, licensing and business development activities. Internet sales (excluding sales of goods requiring licenses) provides additional channels for the commercialisation of products within that category, while online sales of food accommodates the potential offering of a limited range of complementary nutritional products in connection with the Group's existing commercialisation activities, subject to the requisite approvals. These additions are preparatory or ancillary to the Group's existing business and are not expected to result in any material change to its principal business as disclosed in the Prospectus or any change to the disclosed use of IPO proceeds.

Under applicable PRC laws and regulations, where an activity is required to fall within the Company's registered scope of business before it may be conducted, the relevant scope is required to be registered in advance. The Company therefore considers it appropriate to include the above activities in its registered scope of business at this stage so as to accommodate potential future activities, including those that may be preparatory, ancillary or limited in scale. The Company will continue to assess the feasibility and the development of the above and will make further announcement(s) in accordance with the Listing Rules as and when appropriate to inform the Shareholders and potential investors of any further updates.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The proposed amendments to the Articles of Association were duly passed by the Shareholders at the EGM and shall be subject to the completion of the relevant approval, filing and/or registration procedures in China. The full text of the amended Articles of Association is available for download at the website of the Hong Kong Stock Exchange (www.hkexnews.hk) and the Company's website (http://www.mabwell.com).

There is no assurance that any forward-looking statements contained in this announcement regarding the Group's business development, or any matter, will be achieved, will actually occur, will be realised or are complete or accurate. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Mabwell (Shanghai) Bioscience Co., Ltd.
Dr. Liu Datao
Chairman of the Board and Executive Director

Shanghai, the PRC, September 17, 2026

As at the date of this announcement, the directors of the Company are: (i) Mr. Tang Chunshan, Dr. Liu Datao (Chairman of the Board), Dr. Wu Hai, Mr. Hua Jun and Dr. Gui Xun as executive directors; and (ii) Mr. Qin Zhengyu, Mr. Zhou Rui, Ms. Li Fan and Ms. Wang Fang as independent non-executive directors.